Charleston (W.Va.) Area Medical Center, an affiliate of Vandalia Health, in collaboration with the CAMC Clinical Trials Center, is the first site in the world activated for the Bioflow-48 stent study and has enrolled the first three patients globally, according to an Aug. 7 news release from the medical center.
The international trial will evaluate the Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System for treating complex coronary blockages. It will enroll 100 participants across up to 35 sites, including as many as 15 in the U.S.
The study will assess whether using a single long stent to cover long lesions offers better outcomes than implanting multiple overlapping stents.
